{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"100","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"100","upperLimit":"100","value":"100"},{"groupId":"OG002","lowerLimit":"100","upperLimit":"100","value":"100"},{"groupId":"OG003","lowerLimit":"27","upperLimit":"97","value":"83"},{"groupId":"OG004","lowerLimit":"59","upperLimit":"88","value":"77"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"22"}],"units":"Participants"}],"description":"Will utilize either straight Kaplan-Meier based estimators or extensions of nonparametric survival models to account for competing risks.","dispersionType":"95% Confidence Interval","groups":[{"description":"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and 50mg/m2 melphalan hydrochloride IV over 30 minutes on day -2. Patients undergo TBI on day -1.\n\nSTEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.\n\nGVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4, mycophenolate mofetil IV over 2 hours on days 5-35, and sirolimus IV and then PO once tolerated on days 5-180 with a taper beginning on day 100.","id":"OG000","title":"<=50 Years of Age Cohort A"},{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan hydrochloride IV over 30 minutes on day -2. Patients undergo TBI on day -1. Patients recieve 75 mg/m2 Melphalan STEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.\n\nGVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4, mycophenolate mofetil IV over 2 hours on days 5-35, and sirolimus IV and then PO once tolerated on days 5-180 with a taper beginning on day 100.","id":"OG001","title":"<=50 Years of Age Cohort B"},{"description":"Following the administration of Fludarabine 40 mg/m2/day on Days -5 to -2.75 mg/m2 Patients receive 25 mg/m2 Melphalan STEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.\n\nGVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4, mycophenolate mofetil IV over 2 hours on days 5-35, and sirolimus IV and then PO once tolerated on days 5-180 with a taper beginning on day 100.","id":"OG002","title":">50 Years of Age Cohort A -25 mg/m2 Melphalan"},{"description":"Following the administration of Fludarabine 40 mg/m2/day on Days -5 to -2, Patients receive 50 mg/m2 Melphalan STEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.\n\nGVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4, mycophenolate mofetil IV over 2 hours on days 5-35, and sirolimus IV and then PO once tolerated on days 5-180 with a taper beginning on day 100.","id":"OG003","title":">50 Years of Age Cohort B 50 mg/m2 Melphalan"},{"description":"Following the administration of Fludarabine 40 mg/m2/day on Days -5 to -2, patients receive 75 mg/m2 Melphalan STEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.\n\nGVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4, mycophenolate mofetil IV over 2 hours on days 5-35, and sirolimus IV and then PO once tolerated on days 5-180 with a taper beginning on day 100.","id":"OG004","title":">50 Years of Age Cohort C .75 mg/m2 Melphalan"}],"paramType":"NUMBER","populationDescription":"All treated and eligible patients","reportingStatus":"POSTED","timeFrame":"At 1 year","title":"1-Year Progression Free Survival (PFS) Rate Assessed as Per Bone Marrow Transplant (BMT) Standard of Care","type":"SECONDARY","unitOfMeasure":"percentage of participants"}